Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.79)
# 1,747
Out of 4,853 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.12 | +1,864.29% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $9.16 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.06 | +374.31% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $16.45 | +495.74% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $20.82 | +500.38% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.08 | +767.47% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $1.60 | +1,091.22% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.56 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $8.50 | +6,958.82% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $197.11 | -59.83% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $54.38 | +185.03% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.36 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.31 | +480.05% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4,080 | $0.61 | +674,280.17% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.58 | +69,667.44% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $43.43 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.88 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.77 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.41 | +12,151.90% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.68 | +24,356.52% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.99 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $24.00 | +837.70% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.92 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.26 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.12
Upside: +1,864.29%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.16
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.06
Upside: +374.31%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $16.45
Upside: +495.74%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $20.82
Upside: +500.38%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.08
Upside: +767.47%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $1.60
Upside: +1,091.22%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.56
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $8.50
Upside: +6,958.82%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $197.11
Upside: -59.83%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $54.38
Upside: +185.03%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.36
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.31
Upside: +480.05%
Apr 30, 2021
Initiates: Outperform
Price Target: $4,080
Current: $0.61
Upside: +674,280.17%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.58
Upside: +69,667.44%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $43.43
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.88
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $2.77
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.41
Upside: +12,151.90%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.68
Upside: +24,356.52%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.99
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $24.00
Upside: +837.70%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.92
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.26
Upside: -